益气散结方联合阿帕替尼治疗晚期肺癌33例

33 Cases of Advanced Lung Cancer Treatment with Yiqi Sanjie Decoction Combined with Apatinib

目的:探讨益气散结方联合阿帕替尼治疗晚期非小细胞肺癌的临床疗效。方法:回顾我院从2017年1月1日—2018年1月1日期间的63例三线及以上治疗失败的晚期非小细胞肺癌患者。观察组口服益气散结方+阿帕替尼治疗,对照组阿帕替尼单药口服治疗。观察并记录两组疾病控制率、客观缓解率、无进展生存期、ECOG评分、不良反应发生机率。结果:与阿帕替尼单药口服对比,联合益气散结方治疗后患者疾病控制率及客观缓解率虽未明显提高(P>0.05),但中位无进展生存期延长(P<0.05),且生活质量改善,不良反应如手足综合症、蛋白尿的发生率均下降(P<0.05)。结论:益气散结方联合阿帕替尼能延长晚期非小细胞肺癌患者无进展生存期,提高患者的生活质量,减少不良反应发生机率。

Objective:To investigate the clinical efficacy of Yiqi Sanjie decoction combined with apatinib in the treatment of advanced non-small cell lung cancer.Methods:Review the 63 patients with advanced non-small cell lung cancer who failed in treatment of three lines or above from January 1,2017 to June 1,2018.The observation group was treated with Yiqi Sanjie decoction plus apatinib,while the control group was treated with apatinib monotherapy.The disease control rate,objective remission rate,median progression free survival,ECOG score and incidence of adverse reactions were recorded and evaluated in two groups.Results:comparing with the oral administration of apatinib,the disease control rate and the objective remission rate were not significantly increased(P>0.05),but the median progression free survival period was prolonged(P<0.05).At the same time the quality of life was improved while the incidence of side effects such as hand foot syndrome and egg white urine decreased(P<0.05).Conclusion:Yiqi Sanjie decoction combined with apatinib can prolong the life free period of patients with advanced non-small cell lung cancer,improve the quality of life and reduce the incidence of adverse reaction.